Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,968,608
  • Shares Outstanding, K 2,532,900
  • Annual Sales, $ 22,465 M
  • Annual Income, $ 3,001 M
  • 36-Month Beta 0.62
  • Price/Sales 3.98
  • Price/Cash Flow 10.58
  • Price/Book 5.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.29 +2.42%
on 03/26/18
36.75 -4.44%
on 04/10/18
+0.95 (+2.78%)
since 03/23/18
3-Month
32.69 +7.43%
on 03/01/18
36.75 -4.44%
on 04/10/18
-0.74 (-2.06%)
since 01/24/18
52-Week
28.43 +23.53%
on 07/27/17
36.75 -4.44%
on 04/10/18
+4.88 (+16.14%)
since 04/24/17

Most Recent Stories

More News
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)

Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.

AZN : 35.12 (-1.13%)
RHHBY : 27.9200 (+0.14%)
PFE : 37.06 (+0.71%)
BMY : 51.58 (+1.34%)
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

AZN : 35.12 (-1.13%)
JNJ : 126.19 (-0.50%)
MRK : 60.09 (-0.27%)
AGN : 156.90 (-1.87%)
NVS : 76.99 (-0.79%)
RHHBY : 27.9200 (+0.14%)
BMY : 51.58 (+1.34%)
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

AZN : 35.12 (-1.13%)
RHHBY : 27.9200 (+0.14%)
PFE : 37.06 (+0.71%)
BMY : 51.58 (+1.34%)
Model N Founder & CEO Zack Rinat Named Ernst & Young 2018 Entrepreneur of the Year Semifinalist

Model N, Inc. (NYSE: MODN), the leading provider of revenue management solutions for the pharmaceutical, medical device, high tech, manufacturing and semiconductor industries, announced that...

ABT : 58.31 (-0.90%)
AZN : 35.12 (-1.13%)
STX : 58.27 (+0.09%)
NXPI : 101.71 (-1.42%)
MODN : 17.15 (-1.72%)
AMD : 10.09 (+0.50%)
MU : 47.11 (-3.90%)
GILD : 72.72 (-1.74%)
STM : 21.31 (+1.67%)
PFE : 37.06 (+0.71%)
SNY : 39.75 (-0.50%)
Merck's Keytruda Reduces Death Risk in Melanoma Patients

Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.

AZN : 35.12 (-1.13%)
MRK : 60.09 (-0.27%)
LLY : 80.09 (-0.14%)
BMY : 51.58 (+1.34%)
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with...

AZN : 35.12 (-1.13%)
GTHX : 38.87 (-0.66%)
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data

Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.

SPPI : 17.34 (-5.04%)
PTGX : 8.84 (-0.90%)
CATB : 1.64 (-0.61%)
AZN : 35.12 (-1.13%)
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca

Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.

LGND : 161.77 (-3.26%)
AZN : 35.12 (-1.13%)
IONS : 45.33 (-10.59%)
BMY : 51.58 (+1.34%)
Top Analyst Reports for Microsoft, Merck & Union Pacific

Top Analyst Reports for Microsoft, Merck & Union Pacific

MSFT : 93.12 (-2.34%)
COL : 133.03 (unch)
AZN : 35.12 (-1.13%)
UNP : 132.83 (-2.35%)
MRK : 60.09 (-0.27%)
SCHW : 54.49 (-1.59%)
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy

Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status....

AZN : 35.12 (-1.13%)
CLVS : 46.26 (-4.34%)
TSRO : 53.02 (+2.00%)
PFE : 37.06 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 35.64
1st Resistance Point 35.38
Last Price 35.12
1st Support Level 34.93
2nd Support Level 34.75

See More

52-Week High 36.75
Last Price 35.12
Fibonacci 61.8% 33.57
Fibonacci 50% 32.59
Fibonacci 38.2% 31.61
52-Week Low 28.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar